See analyst estimates and all valuation multiples for Nutraceuticals & Cosmeceuticals
| Company | EV | EV/LTM Revenue | EV/LTM EBITDA |
|---|---|---|---|
| $30.2B | 1.9x | 8.0x | |
| $17.1B | 15.1x | 46.4x | |
| $13.8B | 9.7x | 30.5x | |
| $12.1B | 3.6x | 8.6x | |
| $7.2B | 4.7x | 23.3x | |
| $6.2B | 8.4x | 30.6x | |
| $3.7B | 1.7x | 10.4x | |
| $3.2B | 2.3x | 8.4x | |
| $3.2B | 8.5x | 19.5x | |
| $3.0B | 1.4x | 9.5x | |
| $1.9B | n/a | n/a | |
| $1.9B | 1.8x | 7.1x | |
| $1.8B | 6.3x | 12.3x | |
| $1.4B | 2.3x | 11.8x | |
| $1.2B | 7.2x | 25.5x | |
| $1.1B | n/a | n/a | |
| $991M | 4.7x | 17.1x | |
| $956M | 7.6x | 28.6x | |
| $894M | 1.9x | 9.3x | |
| $892M | 3.7x | 9.1x | |
| $821M | n/a | n/a | |
| $735M | 4.7x | 18.5x | |
| $690M | n/a | n/a | |
| $473M | n/a | n/a | |
| $419M | 3.3x | 20.7x | |
| $395M | n/a | n/a | |
| $334M | n/a | n/a | |
| $192M | 2.3x | 13.6x | |
| $187M | 2.9x | n/a | |
| $141M | 2.1x | 13.0x | |
| $77.7M | n/a | n/a | |
| $74.4M | n/a | n/a | |
| $67.8M | 4.4x | 44.4x | |
| $46.2M | 1.3x | 4.5x | |
| $35.8M | n/a | n/a | |
| $31.4M | n/a | n/a | |
| $23.8M | n/a | n/a | |
| $20.6M | 1.1x | -12.0x | |
| $10.8M | 8.6x | -1.0x | |
| $10.0M | n/a | n/a | |
| $6.8M | n/a | n/a | |
| $4.5M | n/a | n/a | |
| -$40K | n/a | n/a |
Valuation multiples as of last 12 months (LTM). Financial data powered by Morningstar, Inc.
See analyst estimates and M&A multiples for Nutraceuticals & Cosmeceuticals